Overview

Minocycline for Bipolar Depression

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate minocycline as a potential treatment for bipolar depression when added to a mood-stabilizing medication. Minocycline is an antibiotic that is approved for the treatment of infections and acne. Participation in this research study is expected to last 8 weeks, and includes five outpatient visits.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Treatments:
Minocycline
Criteria
Inclusion Criteria:

- Meets DSM-IV criteria for Bipolar I Disorder or Bipolar II disorder, depressed phase

- A baseline score of at least 18 on the Montgomery-Asberg Depression Rating Scale
(MADRS)

- Participants on mood stabilizer medication for at least two weeks prior to starting
the study, and must remain on the treatment during the study

- Able to understand English

Exclusion Criteria:

- DSM-IV diagnosis of Bipolar NOS, Cyclothymia, or Schizoaffective Bipolar type

- Pregnant women or women of child bearing potential who are not using a medically
accepted means of contraception (defined as oral contraceptive pill or implant,
condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)

- Serious suicide or homicide risk

- Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
endocrine, neurological, or hematological disease

- Clinical or laboratory evidence of hypothyroidism; if maintained on thyroid medication
must be euthyroid for at least 1 month before visit 1

- Drug/alcohol dependence within past 30 days, or current substance use disorder that
requires detoxification

- Current use of minocycline or history of anaphylactic reaction or intolerance to
minocycline

- Primary clinical diagnosis of antisocial or borderline personality disorder

- Patients with metallic foreign bodies or claustrophobia will be excluded from the MRS
component